BCRX vs MESO: stock comparison and AI forecast
Biocryst Pharmaceuticals Inc (BCRX) and Mesoblast Ltd (MESO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BCRX Biocryst Pharmaceuticals Inc
- Price
- $7.69 -13.6% · 6M
- Market Cap
- $1.97B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MESO Mesoblast Ltd
- Price
- $14.27 -3.6% · 6M
- Market Cap
- $1.83B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BCRX and MESO have similar market capitalizations ($1.97B and $1.83B).
- Over the last six months MESO returned -3.6% and BCRX -13.6%.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BCRX | MESO |
|---|---|---|
| Market Cap | $1.97B | $1.83B |
| EPS | $-1.30 | $-0.25 |
| Revenue/Share | $3.76 | $0.61 |
| FCF/Share | $1.43 | – |
Profitability & Margins
| Metric | BCRX | MESO |
|---|---|---|
| ROA | -60.8% | – |
| ROIC | -73.2% | – |
| Gross Margin | 97.9% | – |
| Operating Margin | -30.1% | – |
| Net Margin | -37.4% | – |
| EBT Margin | -36.9% | -357.5% |
| Tax Rate | -1.4% | -0.3% |
Financial Health
| Metric | BCRX | MESO |
|---|---|---|
| Current Ratio | 2.71x | 1.58x |
| Quick Ratio | 2.64x | 1.41x |
| D/E Ratio | – | 0.36x |
| Financial Leverage | – | 1.36x |
| Interest Coverage | 6.3x | – |
| Working Capital | $335M | $74M |
Cash Flow
| Metric | BCRX | MESO |
|---|---|---|
| Operating Cash Flow | $367M | -$149M |
| Free Cash Flow | $366M | – |
| Capital Spending | -$2M | – |
| OCF Growth YoY | 632.1% | – |
| FCF Growth YoY | 658.3% | – |
| FCF/Sales | 38.0% | – |
| CapEx/Sales | 0.2% | – |
Operational Efficiency
| Metric | BCRX | MESO |
|---|---|---|
| Asset Turnover | 1.63x | 0.10x |
| Receivables Turnover | 7.9x | 1.8x |
| Inventory Turnover | 1.5x | – |
| Fixed Assets Turnover | 578.5x | 43.3x |
| Days Sales Outstanding | 46 days | 204 days |
| Days Inventory | 247 days | – |
| Payables Period | 262 days | – |
| Cash Conversion Cycle | 31 days | – |
Income Statement
| Metric | BCRX | MESO |
|---|---|---|
| Total Revenue | $962M | $78M |
| Operating Income | -$289M | – |
| Net Income | -$360M | – |
| R&D Expense | $211M | $127M |
| SG&A Expense | $321M | – |
| Cost of Goods Sold | $20M | – |
Dividend & Shareholder Information
| Metric | BCRX | MESO |
|---|---|---|
| Shares Outstanding | 256M | 128M |
BCRX vs MESO: stock comparison and AI forecast
Which is bigger, BCRX or MESO?
BCRX and MESO have similar market capitalizations ($1.97B and $1.83B).
Which stock performed better over the last six months, BCRX or MESO?
Over the last six months MESO returned -3.6% and BCRX -13.6%.
Which one does Intratio's AI model rank higher, BCRX or MESO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.